Sivelestat sodium hydrate improves septic acute lung injury by reducing alveolar dysfunction

• Published in: Research communications in molecular pathology and pharmacology Vol. 119; no. 1-6; p. 53
• Main Authors: Endo, Shigeatsu, Sato, Nobuhiro, Yaegashi, Yasunori, Suzuki, Yasushi, Kojika, Masahiro, Yamada, Yasuhiko, Yoshida, Yuki, Nakadate, Toshihide, Aoki, Hidehiko, Inoue, Yoshihiro
• Format: Journal Article
• Language: English
• Published: United States 2006
• Subjects: Acute Disease; Adolescent; Adult; Aged; Glycine - administration & dosage; Glycine - analogs & derivatives; Glycine - therapeutic use; Humans; Interleukin-8 - blood; Leukocyte Elastase - antagonists & inhibitors; Leukocyte Elastase - blood; Leukocytes - drug effects; Middle Aged; Oxygen - blood; Pulmonary Circulation - drug effects; Pulmonary Surfactant-Associated Protein D - blood; Respiration, Artificial - statistics & numerical data; Serine Proteinase Inhibitors - administration & dosage; Serine Proteinase Inhibitors - therapeutic use; Sulfonamides - administration & dosage; Sulfonamides - therapeutic use; Survival Analysis; Systemic Inflammatory Response Syndrome - drug therapy; Systemic Inflammatory Response Syndrome - immunology; Treatment Outcome; Tumor Necrosis Factor-alpha - blood
• ISSN: 1078-0297

Sivelestat sodium hydrate (sivelestat) is a selective inhibitor of polymorphonuclear leukocyte elastase (PMN-E). We administered sivelestat to patients with septic acute lung injury (ALI) to examine its usefulness. The primary endpoints in the study were the duration of artificial ventilation and pu...